UBS Group
DMII

UBS Group’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

UBS Group’s Portfolio DMII Stock Details DMII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$439K Sell
43,668
-1,067
-2% -$10.7K ﹤0.01% 6325
2026
Q1 		$446K Buy
+44,735
New +$446K ﹤0.01% 6160

Other funds holding DMII

KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

UBS Group's DMII Position: Q2 2026 in Review

UBS Group reduced its Drugs Made In America Acquisition II Corp (DMII) stake by 2.4% in Q2 2026, selling an estimated $10.7K and leaving 43,668 shares worth $439K. The position accounts for ﹤0.01% of the portfolio, ranked #6325.

UBS Group first reported a position in DMII in Q1 2026 and has held it in 2 quarters since. The position peaked at $446K in Q1 2026. 69 funds tracked by Wall St. Rank hold DMII as of Q2 2026.

  • UBS Group held 43,668 shares of Drugs Made In America Acquisition II Corp worth $439K as of Q2 2026.
  • UBS Group sold 1,067 Drugs Made In America Acquisition II Corp shares in Q2 2026, an estimated $10.7K.
  • Drugs Made In America Acquisition II Corp made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6325 holding.
  • UBS Group first reported a position in Drugs Made In America Acquisition II Corp in Q1 2026 and has held it in 2 quarters since.
  • UBS Group's Drugs Made In America Acquisition II Corp position peaked at $446K in Q1 2026.
  • 69 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.